Lung cancer

• 1. Global Disease Burden And Epidemiology

  ›

  In 2020, the world witnessed 2.2 million new cases of lung cancer and 1.8 million deaths from the disease. This single malignancy accounted for 18% of all global cancer fatalities that year. The median age at diagnosis stands at 70 years, while the average age at death is 72. Lung cancer remains exceptionally rare among individuals younger than 40, with incidence rates climbing steadily as populations age until stabilizing around 80. Geographic patterns reveal stark disparities, with the highest incidence rates found in Micronesia, Polynesia, Europe, Asia, and North America. Conversely, Africa and Central America report significantly lower rates. Globally, approximately 8% of men and 6% of women develop lung cancer during their lifetimes. The ratio of male to female cases varies dramatically by region, reaching nearly 12:1 in Belarus but dropping to 1:1 in Brazil. These demographic shifts reflect deep differences in smoking habits across cultures. Projections suggest annual deaths could rise to nearly 3 million by 2035 due to aging populations and persistent tobacco use.

  12

• 2. Genetic Origins And Pathogenesis Mechanisms

  ›

  The fundamental driver of lung cancer lies within genetic damage to the DNA of airway cells. This damage typically results from breathing toxic substances like cigarette smoke or occurs randomly through natural cellular processes. Mutations cause a loss of function in tumor suppressor genes or a gain of function in oncogenes. Driver mutations are particularly common in adenocarcinomas and often occur in receptor tyrosine kinases such as EGFR, BRAF, MET, KRAS, and PIK3CA. In contrast, small-cell lung cancers rarely feature these specific driver mutations. Instead, they frequently harbor mutations that inactivate the tumor suppressors p53 and RB. A cluster of tumor suppressor genes on the short arm of chromosome 3 is often lost early in the development of all lung cancers. These genetic changes allow cells to multiply endlessly, stimulate blood vessel growth, avoid programmed cell death, and eventually spread into surrounding tissue. Different tumors acquire these abilities through distinct mutation pathways, though generally cancer-contributing mutations activate oncogenes and inactivate tumor suppressors. A given tumor will typically possess just one primary driver mutation.

  143

• 3. Risk Factors From Tobacco To Environment

  ›

  Tobacco smoking causes 80% to 90% of all lung cancer cases worldwide. The risk increases directly with the quantity of cigarettes consumed over time. Chemicals within tobacco smoke create DNA adducts, oxidative stress, and breaks in DNA strands. At least 50 chemicals in cigarette smoke are identified as carcinogenic by the International Agency for Research on Cancer. Passive smoking also poses a significant threat; living with a smoker increases one's risk by 24%. Environmental exposures contribute another layer of danger. Asbestos exposure accounts for 9, 15% of cases and acts synergistically with smoking to drastically elevate mortality risks. Radon gas, a naturally occurring radioactive element, is responsible for between 3% and 14% of cases. Underground miners historically faced the greatest exposure, yet residential radon levels can still increase occupants' risk. Other occupational hazards include arsenic used in wood preservation, ionizing radiation from uranium mining, vinyl chloride in papermaking, beryllium in jewelry making, chromium in stainless steel production, nickel in electroplating, and diesel exhaust encountered by miners. Air pollution from motor vehicle exhaust and fossil fuel-burning power plants further elevates global incidence.

  91011

• 4. Diagnostic Imaging And Histological Classification

  ›

  Early lung cancer often presents no symptoms, requiring medical imaging for detection. Primary care providers typically begin with a chest X-ray to identify masses or widening of the mediastinum. Computed tomography scans reveal tumor sizes and locations more clearly than standard X-rays. Definitive diagnosis requires a biopsy examined under a microscope by a pathologist. Biopsies are often obtained through minimally invasive techniques like fiberoptic bronchoscopy or fine needle aspiration. Liquid biopsies may detect circulating tumor DNA when tissue samples cannot be retrieved. Positron emission tomography scanning locates metastases throughout the body. Lung cancer is classified into two main types based on cell appearance: small-cell lung cancer and non-small-cell lung cancer. Small-cell lung cancer comprises 15% of cases and features cells with ill-defined boundaries and granular-looking chromatin. Non-small-cell lung cancers make up 85% of cases and include adenocarcinomas, squamous-cell carcinomas, and large-cell carcinomas. Adenocarcinomas account for nearly 40% of all cases and grow in three-dimensional clumps resembling glandular cells. Squamous-cell carcinomas represent about 30% and consist of sheets of cells with layers of keratin. Large-cell carcinomas comprise less than 10% and feature large nuclei with conspicuous nucleoli.

  234

• 5. Treatment Protocols And Therapeutic Advances

  ›

  Surgical removal remains the first-line treatment for early-stage non-small-cell lung cancer. Procedures range from wedge resections to full pneumonectomies depending on tumor location and patient health. Stereotactic body radiation therapy serves as best practice for those unable or unwilling to undergo surgery. Chemotherapy regimens typically involve platinum-based drugs like cisplatin combined with etoposide or carboplatin. For later stages, targeted molecular therapies address specific genetic mutations. Up to 30% of tumors harbor EGFR gene mutations treatable with inhibitors such as osimertinib or erlotinib. Approximately 7% of cases feature hyperactive ALK protein managed by inhibitors like crizotinib or alectinib. Immune checkpoint inhibitors prevent cancer cells from inactivating immune T cells. These drugs are most effective against tumors expressing the PD-L1 protein. Palliative care integrates pain management and symptom relief into all treatment phases. The World Health Organization recommends a three-tiered system for managing cancer pain ranging from acetaminophen to opioid medications. Prophylactic cranial irradiation reduces brain metastasis risks in small-cell lung cancer patients. Survival rates vary significantly by stage; early-stage IA1 disease boasts a five-year survival of 92%, while advanced IVB disease has zero percent five-year survival.

  65

• 6. Historical Discovery And Public Health Response

  ›

  Lung cancer was uncommon before the advent of cigarette smoking in the 20th century. Surgeon Alton Ochsner recalled his medical school class in 1919 being summoned to witness an autopsy of a man who died from the disease. Isaac Adler's 1912 book Primary Malignant Growths of the Lungs and Bronchi called the condition among the rarest forms of disease. By the 1920s, theories linked rising incidence to chemical exposures including tobacco smoke and industrial air pollution. Growing scientific evidence emerged through the 1940s and 1950s via case-control studies showing smokers were at dramatically increased risk. A 1953 study demonstrating that tar from cigarette smoke caused tumors in mice attracted attention in Life and Time magazines. Facing public concern, six American tobacco company CEOs enlisted Hill & Knowlton to declare the link controversial. The United Kingdom's Royal College of Physicians officially concluded smoking causes lung cancer in 1962. The US Surgeon General's report published in January 1964 firmly stated smoking far outweighed all other factors in causing the disease. The first successful pneumonectomy occurred in 1933 by Evarts Graham at Barnes Hospital in St. Louis. Surgical techniques evolved over decades with video-assisted thoracoscopic surgery becoming widely performed in the 1980s.

  11